Investors & Media
Reports
- All
-
- All
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- All
-
- All
- Quarterly Report
- Semiannual report
- Annual Report
-
Ryvu Therapeutics Q3 2023 Financial Report
29/11/20232023
Ryvu Therapeutics Q3 2023 Report
Ryvu Therapeutics Financial Statements Q3 2023
-
Ryvu Therapeutics H1 2023 Financial Report
13/09/20232023
Semiannual report
Ryvu Therapeutics H1 2023 Report
Ryvu Therapeutics Financial Statements H1 2023
Independent Auditor’s Report On Review Of Interim Financial Statements
-
Ryvu Therapeutics S.A. Q1 2023 Financial Report
16/05/20232023
Quarterly Report
Ryvu Therapeutics Q1 2023 Report
Ryvu Therapeutics Financial Statements Q1 2023
-
Ryvu Therapeutics S.A. Annual Report 2022
24/03/20232022
Annual Report
Letter to Shareholders from CEO of Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. Annual Report 2022
Ryvu Therapeutics S.A. Financial Statements 2022
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statements for 2022
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - functioning of the Audit Committee and the Auditor
Auditor’s opinion on the annual financial statements of Ryvu Therapeutics S.A.
-
Ryvu Therapeutics S.A. Q3 2022 Financial Report
23/11/20222022
Ryvu Therapeutics Q3 2022 Report
Ryvu Therapeutics Financial Statements Q3 2022
-
Ryvu Therapeutics H1 2022 Financial Report
29/09/20222022
Ryvu Therapeutics H1 2022 Report
Ryvu Therapeutics Financial Statements H1 2022
Independent Auditor’s Report On Review Of Interim Financial Statements
-
Ryvu Therapeutics S.A. Q1 2022 Financial Report
18/05/20222022
Quarterly Report
Ryvu Therapeutics Q1 2022 Report
Ryvu Therapeutics Financial Statements Q1 2022
-
Ryvu Therapeutics S.A. Annual Report 2021
15/03/20222021
Letter to Shareholders from CEO of Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. Annual Report 2021
Ryvu Therapeutics S.A. Financial Statements 2021
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statements for 2021
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - functioning of the Audit Committee and the Auditor
Auditor’s opinion on the annual financial statements of Ryvu Therapeutics S.A.
-
Ryvu Therapeutics S.A. Q3 2021 Financial Report
10/11/20212021
Ryvu Therapeutics Q3 2021 Report
Ryvu Therapeutics Financial Statements Q3 2021
-
Ryvu Therapeutics H1 2021 Financial Report
08/09/20212021
Ryvu Therapeutics H1 2021 Report
Ryvu Therapeutics Financial Statements H1 2021
Independent Auditor’s Report On Review Of Interim Financial Statements
-
Ryvu Therapeutics S.A. Q1 2021 Financial Report
12/05/20212021
Ryvu Therapeutics Q1 2021 Report
Ryvu Therapeutics Financial Statements Q1 2021
-
Ryvu Therapeutics S.A. Annual Report 2020
16/03/20212021
Annual Report
Letter to Shareholders from CEO of Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. Annual Report 2020
Ryvu Therapeutics S.A. Financial Statements 2020
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statement for 2020
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - functioning of the Audit Committee and the Auditor
Auditor’s opinion on the annual financial statements of Ryvu Therapeutics S.A.
-
Ryvu Therapeutics S.A. Q3 2020 Financial Report
19/11/20202020
Ryvu Therapeutics Q3 2020 Report
Ryvu Therapeutics Financial Statements Q3 2020
-
Ryvu Therapeutics 2020 H1 Financial Report
15/09/20202020
Semiannual report
Ryvu Therapeutics 2020 H1 Financial Report
Ryvu Therapeutics 2020 H1 Financial Statements
Independent Auditor’s Report On Review Of Interim Financial Statements
-
Ryvu Therapeutics S.A. Q1 2020 Financial Report
10/06/20202020
Quarterly Report
Ryvu Therapeutics Q1 2020 Financial Report - Additional Information
Ryvu Therapeutics Financial Statements Q1 2020
Independent Auditor’s Report On Review Of Interim Financial Statements
-
Ryvu Therapeutics S.A. Annual Report (Summary) 2019
09/04/20202020
Annual Report
Letter to Shareholders from CEO of Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. Annual Report (Summary) 2019
Ryvu Therapeutics S.A. Financial Statements 2019
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - functioning of the Audit Committee and the Auditor
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statement for 2019
Auditor’s opinion on the annual financial statements of Ryvu Therapeutics S.A.
-
Raport ESPI QSr 03/2019
06/11/20192019
Quarterly Report
Consolidated Quarterly Report Ryvu Therapeutics 2019 Q3 (Summary)
-
Report ESPI PSr 2019
05/09/20192019
Semiannual report
Consolidated Semiannual Report Selvita Group 2019 H1 (Summary)
-
Report ESPI QSr 01/2019
22/05/20192019
Quarterly Report
Consolidated Quarterly Report Selvita Group 2019 Q1 (Summary)
-
Report ESPI QSr 03/2018
13/11/20182018
Quarterly Report
Consolidated Quarterly Report Selvita Group 2018 Q3 (Summary)
-
Report ESPI – SA-R 2018
21/09/20182018
Annual Report
Selvita Group Annual Report 2018 (Summary)
-
Report ESPI PSr 2018
28/08/20182018
Semiannual report
Consolidated Semiannual Report Selvita Group 2018 H1 (Summary)
-
Report ESPI QSr 01/2018
21/05/20182018
Quarterly Report
Consolidated Quarterly Report Selvita Group 2018 Q1 (Summary)
-
Report ESPI QSr 03/2017
15/11/20172017
Quarterly Report
Consolidated Quarterly Report Selvita Group 2017 Q3 (Summary)
-
Report ESPI – SA-R 2017
21/09/20172017
Annual Report
Selvita Group Annual Report 2017 (Summary)
-
Report ESPI PSr 2017
11/09/20172017
Semiannual report
Consolidated Semiannual Report Selvita Group 2017 H1 (Summary)
-
Report ESPI QSr 01/2017
30/05/20172017
Quarterly Report
Consolidated Quarterly Report Selvita Group 2017 Q1 (Summary)
-
Report ESPI QSr 03/2016
09/11/20162016
Quarterly Report
Consolidated Quarterly Report Selvita Group 2016 Q3 (Summary)
-
Report ESPI – SA-R 2016
21/09/20162016
Annual Report
Selvita Group Annual Report 2016 (Summary)
-
Report ESPI PSr 2016
30/08/20162016
Semiannual report
Consolidated Semiannual Report Selvita Group 2016 H1 (Summary)
-
Report ESPI QSr 01/2016
12/05/20162016
Quarterly Report
Consolidated Quarterly Report Selvita Group 2016 Q1 (Summary)
-
Report ESPI QSr 03/2015
05/11/20152015
Quarterly Report
Consolidated Quarterly Report Selvita Group 2015 Q3 (Summary)
-
Report ESPI – SA-R 2015
21/09/20152015
Annual Report
Selvita Group Annual Report 2015 (Summary)
-
Report ESPI PSr 2015
13/08/20152015
Semiannual report
Consolidated Semiannual Report Selvita Group 2015 H1 (Summary)
-
Report ESPI QSr 01/2015
12/05/20152015
Quarterly Report
Consolidated Quarterly Report Selvita Group 2015 Q1 (Summary)
-
Report EBI 30/2014
06/11/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q3
-
Report ESPI – SA-R 2014
21/09/20142014
Annual Report
Selvita Group Annual Report 2014 (Summary)
-
Report EBI 27/2014
07/08/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q2
-
Report EBI 15/2014
13/05/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q1
-
Report EBI 07/2014
01/02/20142013
Quarterly Report
Consolidated Quarterly Report Selvita Group 2013 Q4
-
Report EBI 28/2013
01/11/20132013
Quarterly Report
Consolidated Quarterly Report Selvita Group 2013 Q3
- All
-
- All
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
-
Current Report ESPI 47/2023
07/12/2023Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023
2023
-
Current Report ESPI 46/2023
02/11/2023Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting
2023
-
Current Report ESPI 45/2023
23/10/2023Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update
2023
-
Current Report ESPI 44/2023
20/10/2023Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes
2023
-
Current Report ESPI 43/2023
16/10/2023RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023
2023
-
Current Report ESPI 42/2023
16/10/2023Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
2023
-
Current Report ESPI 41/2023
04/10/2023Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
2023
-
Current Report ESPI 40/2023
14/09/2023Conclusion of an amendment to global License Agreement with Menarini Group
2023
-
Current Report ESPI 39/2023
04/08/2023Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
2023
-
Current Report ESPI 38/2023
31/07/2023Conclusion of a financing agreement with the Medical Research Agency
2023
-
Current Report ESPI 37/2023
31/07/2023Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
2023
-
Current Report ESPI 36/2023
21/07/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 35/2023
14/07/2023Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
2023
-
Current Report ESPI 34/2023
06/07/2023Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
2023
-
Current Report ESPI 33/2023
19/06/2023Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
2023
-
Current Report ESPI 32/2023
14/06/2023Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 31/2023
14/06/2023Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
2023
-
Current Report ESPI 30/2023
14/06/2023Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 29/2023
13/06/2023Recommendation of Ryvu’s project for funding by the Medical Research Agency
2023
-
Current Report ESPI 28/2023
09/06/2023Publication of the updated clinical and preclinical data on RVU120
2023
-
Current Report ESPI 22K/2023
26/05/2023Correction of the current report on the convening of the Company’s Annual General Meeting
2023
-
Current Report ESPI 27/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 26/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 25/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 24/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2023
-
Current Report ESPI 23/2023
23/05/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 22/2023
18/05/2023Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 21/2023
16/05/2023Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 20/2023
11/05/2023New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
2023
-
Current Report ESPI 19/2023
05/05/2023Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
2023
-
Current Report ESPI 18/2023
20/04/2023Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
2023
-
Current Report ESPI 17/2023
12/04/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 16/2023
06/04/2023Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV
2023
-
Current Report ESPI 15/2023
10/03/2023Change of publication date of the annual report for 2022
2023
-
Current Report ESPI 14/2023
02/03/2023Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
2023
-
Current Report ESPI 13/2023
06/02/2023Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
2023
-
Current Report ESPI 12/2023
03/02/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 11/2023
03/02/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 10/2023
26/01/2023Achievement of the first milestone under licence agreement with Exelixis Inc.
2023
-
Current Report ESPI 07/2023
25/01/2023Announcement of the NDS on registration of series J shares with the NDS
2023
-
Current Report ESPI 09/2023
25/01/2023Publication dates for periodic reports in 2023
2023
-
Current Report ESPI 08/2023
25/01/2023Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 06/2023
20/01/2023Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
2023
-
Current Report ESPI 05/2023
20/01/2023Conditional registration of the series J shares of the Company with the National Depository for Securities
2023
-
Current Report ESPI 04/2023
19/01/2023Notification from a shareholder of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 03/2023
18/01/2023Notification from a shareholder of a change in his share in the total number of votes in the Company
2023
-
Current Report ESPI 02/2023
18/01/2023Registration of amendment of the Company’s Articles of Association concerning share capital
2023
-
Current Report ESPI 01/2023
09/01/2023Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 35/2022
22/12/2022Notification from a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
2022
-
Current Report ESPI 34/2022
22/12/2022Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
2022
-
Current Report ESPI 33/2022
22/12/2022Summary of the subscription of ordinary bearer series J shares
2022
-
Current Report ESPI 32/2022
22/12/2022Allotment of series J shares
2022
-
Current Report ESPI 31/2022
15/12/2022Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering
2022
-
Current Report ESPI 30/2022
11/12/2022Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
2022
-
Current Report ESPI 29/2022
07/12/2022Approval of the prospectus of the Company
2022
-
Current Report ESPI 28/2022
02/12/2022Decision to conduct public offering of J series shares in December 2022
2022
-
Current Report ESPI 27/2022
30/11/2022Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration
2022
-
Current Report ESPI 26/2022
30/11/2022Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE
2022
-
Current Report ESPI 25/2022
03/11/2022Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting
2022
-
Current Report ESPI 24/2022
26/10/2022Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
2022
-
Current Report ESPI 23/2022
12/10/2022Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
2022
-
Current Report ESPI 22/2022
05/10/2022Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
2022
-
Current Report ESPI 21/2022
03/10/2022Registration of an amendment to the Company’s Articles of Association
2022
-
Current Report ESPI 20/2022
19/09/2022Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
2022
-
Current Report ESPI 19/2022
19/09/2022Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 18/2022
14/09/2022Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
2022
-
Current Report ESPI 17/2022
19/08/2022Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 16/2022
19/08/2022Ryvu Therapeutics’ development plans for 2022-2024
2022
-
Current Report ESPI 15/2022
18/08/2022Change of the date of publication of the periodic report for the first half of 2022
2022
-
Current Report ESPI 14/2022
17/08/2022Conclusion of a financing agreement with the European Investment Bank
2022
-
Current Report ESPI 13/2022
26/07/2022Changes in Ryvu’s Management Board
2022
-
Current Report ESPI 12/2022
08/07/2022Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
2022
-
Current Report ESPI 11/2022
07/07/2022Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
2022
-
Current Report ESPI 10/2022
01/07/2022Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
2022
-
Current Report ESPI 09/2022
01/07/2022Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 08/2022
10/06/2022Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
2022
-
Current Report ESPI 07/2022
03/06/2022Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 06/2022
12/05/2022New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
2022
-
Current Report ESPI 05/2022
27/04/2022Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
2022
-
Current Report ESPI 04/2022
01/04/2022Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2022
-
Current Report ESPI 03/2022
08/03/2022Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting
2022
-
Current Report ESPI 02/2022
19/01/2022Publication dates for periodic reports in 2022
2022
-
Current Report ESPI 01/2022
19/01/2022Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center
2022
-
Current Report ESPI 40/2021
30/12/2021Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
2021
-
Current Report ESPI 39/2021
20/12/2021Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
2021
-
Current Report ESPI 38/2021
17/12/2021Change order to the statement of work
2021
-
Current Report ESPI 37/2021
14/12/2021Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases
2021
-
Current Report ESPI 36/2021
13/12/2021Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
2021
-
Current Report ESPI 35/2021
19/11/2021Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2021
-
Current Report ESPI 34/2021
09/11/2021Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference
2021
-
Current Report ESPI 33/2021
04/11/2021Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
2021
-
Current Report ESPI 32/2021
04/11/2021Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)
2021
-
Current Report ESPI 31/2021
24/09/2021Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center
2021
-
Current Report ESPI 30/2021
25/08/2021First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
2021
-
Current Report ESPI 29/2021
25/08/2021Resignation of the Member of the Management Board
2021
-
Current Report ESPI 28/2021
18/08/2021Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company
2021
-
Current Report ESPI 27/2021
13/08/2021Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2021
-
Current Report ESPI 26/2021
21/07/2021Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 25/2021
14/07/2021FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome
2021
-
Current Report ESPI 24/2021
13/07/2021Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 23/2021
09/07/2021Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings
2021
-
Current Report ESPI 22K/2021
08/07/2021Correction of the current report No. 22/2021 of July 8, 2021
2021
-
Current Report ESPI 22/2021
08/07/2021Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company
2021
-
Current Report ESPI 21/2021
30/06/2021Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021
2021
-
Current Report ESPI 20/2021
30/06/2021Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 19/2021
11/06/2021Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)
2021
-
Current Report ESPI 18/2021
02/06/2021Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 18/2021
28/05/2021Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
2021
-
Current Report ESPI 16/2021
20/05/2021Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021
2021
-
Current Report ESPI 15/2021
17/05/2021Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021
2021
-
Current Report ESPI 14/2021
17/05/2021Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 13/2021
13/05/2021Information concerning impact of non-diluting incentive program on Company’s financial statements
2021
-
Current Report ESPI 12/2021
12/05/2021New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021
2021
-
Current Report ESPI 10/2021
20/04/2021Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024
2021
-
Current Report ESPI 09/2021
08/04/2021Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021
-
Current Report ESPI 08/2021
08/04/2021Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 07/2021
18/03/2021Conclusion of the grant agreement with the National Center for Research and Development
2021
-
Current Report ESPI 06/2021
11/03/2021Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting
2021
-
Current Report ESPI 05/2021
08/03/2021Conclusion of an agreement concerning operational execution of Phase I clinical trial of RVU120 (SEL120) in solid tumors
2021
-
Current Report ESPI 04/2021
18/01/2021Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
2021
-
Current Report ESPI 03/2021
13/01/2021Publication dates for periodic reports in 2021
2021
-
Current Report ESPI 02/2021
07/01/2021Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
2021
-
Current Report ESPI 01/2021
04/01/2021The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 43/2020
01/12/2020Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
2020
-
Current Report ESPI 42/2020
23/11/2020Appointment of the new Management Board Member of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 40/2020
21/10/2020Revision of the Company’s research project pipeline
2020
-
Current Report ESPI 39/2020
14/10/2020Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020
2020
-
Current Report ESPI 38/2020
12/10/2020Change of the registered office address of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 36/2020
16/09/2020First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703
2020
-
Current Report ESPI 34/2020
01/09/2020Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office
2020
-
Current Report ESPI 33/2020
31/08/2020Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. held on August 31, 2020
2020
-
Current Report ESPI 32/2020
31/08/2020Resolutions adopted by the Annual General Shareholders Meeting of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 31/2020
26/08/2020Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares
2020
-
Current Report ESPI 29/2020
19/08/2020Registration of share capital increase
2020
-
Current Report ESPI 28/2020
05/08/2020Completion of the subscription of Series I Shares
2020
-
Current Report ESPI 26/2020
30/07/2020Introduction of the Rights to Series I Shares to trading on the main market operated by the WSE
2020
-
Current Report ESPI 25/2020
27/07/2020Registration of the Rights to Series I Shares in the book-entry form by the National Depository for Securities
2020
-
Current Report ESPI 24/2020
22/07/2020Execution of subscription agreements and collection of cash contributions relating to series I shares in Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 23/2020
15/07/2020Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement
2020
-
Current Report ESPI 22/2020
13/07/2020Ryvu Therapeutics S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription of new Series I ordinary bearer shares issued by Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 21/2020
13/07/2020Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. convened on July, 13 2020
2020
-
Current Report ESPI 20/2020
13/07/2020Resolutions adopted by the General Meeting of Ryvu Therapeutics S.A.
2020
-
Raport bieżący ESPI 18/2020
15/06/2020Ryvu Therapeutics Strategy for 2020-2022
2020
